Table 1 Baseline characteristics of the study population (N = 562)
Characteristica | IC (N = 271) | LIT without Ven (N = 237) | HMA + Ven (N = 54) | P value |
|---|---|---|---|---|
Age | ||||
 Median (years) | 65 (21–91) | 73 (53–92) | 71 (42–84) |  < 0.0001 |
 ≥ 60 years | 191 (70) | 226 (95) | 50 (93) |  < 0.0001 |
Preceding diagnosis | ||||
 MDS | 236 (87) | 204 (86) | 43 (80) | 0.35 |
 CMML | 35 (13) | 33 (14) | 11 (20) | |
Prior therapies | ||||
 Prior allogeneic HSCT | 31 (11) | 13 (5) | 10 (19) | 0.005 |
 Median number of prior therapies | 1 (1–5) | 1 (1–5) | 1 (1–3) | 0.65 |
Cytogenetics | ||||
 Diploid | 82 (30) | 91 (38) | 16 (30) | 0.31 |
 Non-diploid, non-adverse | 56 (21) | 45 (19) | 7 (13) | |
 Adverse | 111 (41) | 81 (34) | 25 (46) | |
 IM/ND | 22 (8) | 20 (9) | 6 (11) | |
Mutation | ||||
 ASXL1 | 36/102 (35) | 24/101 (26) | 13/54 (24) | 0.14 |
 DNMT3A | 15/139 (11) | 23/150 (15) | 12/54 (22) | 0.12 |
 FLT3 D835 | 3/247 (1) | 7/232 (3) | 0 | 0.38 |
 FLT3-ITD | 12/247 (5) | 25/232 (11) | 1/54 (2) | 0.01 |
 IDH1 | 10/166 (6) | 10/171 (6) | 6/54 (11) | 0.37 |
 IDH2 | 12/167 (7) | 11/170 (6) | 4/54 (7) | 0.94 |
 NPM1 | 11/191 (6) | 14/189 (7) | 1/54 (2) | 0.31 |
 KRAS/NRAS | 37/241 (15) | 47/224 (21) | 7/54 (13) | 0.18 |
 RUNX1 | 23/101 (23) | 26/101 (26) | 16/54 (30) | 0.64 |
 TET2 | 25/107 (23) | 27/104 (26) | 12/54 (22) | 0.85 |
 TP53 | 46/144 (32) | 31/152 (20) | 18/54 (33) | 0.04 |